Emergency Department, Hôpital Bichat, Assistance Publique - Hôpitaux de Paris, and Université Paris Cité, IAME (Infection, Antimicrobial, Modelisation, Evolution), Inserm, Paris, France (D.B.).
Virology Department, Hôpital Bichat, Assistance Publique - Hôpitaux de Paris, and Université Paris Cité, IAME (Infection, Antimicrobial, Modelisation, Evolution), Inserm, Paris, France (B.V.).
Ann Intern Med. 2022 Jun;175(6):831-837. doi: 10.7326/M22-0308. Epub 2022 Mar 15.
At the end of 2021, the B.1.1.529 SARS-CoV-2 variant (Omicron) wave superseded the B.1.617.2 variant (Delta) wave.
To compare baseline characteristics and in-hospital outcomes of patients with SARS-CoV-2 infection with the Delta variant versus the Omicron variant in the emergency department (ED).
Retrospective chart reviews.
13 adult EDs in academic hospitals in the Paris area from 29 November 2021 to 10 January 2022.
Patients with a positive reverse transcriptase polymerase chain reaction (RT-PCR) test result for SARS-CoV-2 and variant identification.
Main outcome measures were baseline clinical and biological characteristics at ED presentation, intensive care unit (ICU) admission, mechanical ventilation, and in-hospital mortality.
A total of 3728 patients had a positive RT-PCR test result for SARS-CoV-2 during the study period; 1716 patients who had a variant determination (818 Delta and 898 Omicron) were included. Median age was 58 years, and 49% were women. Patients infected with the Omicron variant were younger (54 vs. 62 years; difference, 8.0 years [95% CI, 4.6 to 11.4 years]), had a lower rate of obesity (8.0% vs. 12.5%; difference, 4.5 percentage points [CI, 1.5 to 7.5 percentage points]), were more vaccinated (65% vs. 39% for 1 dose and 22% vs. 11% for 3 doses), had a lower rate of dyspnea (26% vs. 50%; difference, 23.6 percentage points [CI, 19.0 to 28.2 percentage points]), and had a higher rate of discharge home from the ED (59% vs. 37%; difference, 21.9 percentage points [-26.5 to -17.1 percentage points]). Compared with Delta, Omicron infection was independently associated with a lower risk for ICU admission (adjusted difference, 11.4 percentage points [CI, 8.4 to 14.4 percentage points]), mechanical ventilation (adjusted difference, 3.6 percentage points [CI, 1.7 to 5.6 percentage points]), and in-hospital mortality (adjusted difference, 4.2 percentage points [CI, 2.0 to 6.5 percentage points]).
Patients with COVID-19 illness and no SARS-CoV-2 variant determination in the ED were excluded.
Compared with the Delta variant, infection with the Omicron variant in patients in the ED had different clinical and biological patterns and was associated with better in-hospital outcomes, including higher survival.
None.
2021 年底,B.1.1.529 SARS-CoV-2 变异株(奥密克戎)取代了 B.1.617.2 变异株(德尔塔)。
比较急诊科(ED)中感染 SARS-CoV-2 的德尔塔变异株与奥密克戎变异株患者的基线特征和住院结局。
回顾性图表审查。
2021 年 11 月 29 日至 2022 年 1 月 10 日,巴黎地区 13 家学术医院的成人 ED。
SARS-CoV-2 阳性逆转录酶聚合酶链反应(RT-PCR)检测结果和变异体鉴定的患者。
主要结局指标为 ED 就诊时、入住重症监护病房(ICU)、机械通气和院内死亡率的基线临床和生物学特征。
在研究期间,共有 3728 例患者的 SARS-CoV-2 RT-PCR 检测结果呈阳性;其中 1716 例患者进行了变异体确定(818 例德尔塔和 898 例奥密克戎)。中位年龄为 58 岁,49%为女性。感染奥密克戎变异株的患者更年轻(54 岁比 62 岁;差异为 8.0 岁[95%CI,4.6 至 11.4 岁]),肥胖率较低(8.0%比 12.5%;差异为 4.5 个百分点[CI,1.5 至 7.5 个百分点]),接种疫苗的比例较高(1 剂疫苗接种率为 65%,3 剂疫苗接种率为 22%,而德尔塔变异株为 39%和 11%),呼吸困难发生率较低(26%比 50%;差异为 23.6 个百分点[CI,19.0 至 28.2 个百分点]),从 ED 出院回家的比例较高(59%比 37%;差异为 21.9 个百分点[-26.5 至-17.1 个百分点])。与德尔塔相比,奥密克戎感染与 ICU 入院(调整差异,11.4 个百分点[CI,8.4 至 14.4 个百分点])、机械通气(调整差异,3.6 个百分点[CI,1.7 至 5.6 个百分点])和院内死亡率(调整差异,4.2 个百分点[CI,2.0 至 6.5 个百分点])的风险降低独立相关。
ED 中无 COVID-19 疾病且无 SARS-CoV-2 变异体确定的患者被排除在外。
与德尔塔变异株相比,ED 中奥密克戎变异株感染的患者具有不同的临床和生物学特征,与更好的住院结局相关,包括生存率更高。
无。